BioMark Diagnostics Inc.
BUX
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -6.45% | -1.28% | 1.53% | 4.22% | 14.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.45% | -1.28% | 1.53% | 4.22% | 14.38% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -6.45% | -1.28% | 1.53% | 4.22% | 14.38% |
| SG&A Expenses | 25.49% | 13.41% | -6.25% | -23.50% | -30.39% |
| Depreciation & Amortization | -31.22% | -18.76% | -12.06% | -0.21% | -8.24% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.26% | 15.00% | -0.17% | -7.89% | -16.26% |
| Operating Income | -7.44% | -16.46% | 0.33% | 8.92% | 18.30% |
| Income Before Tax | -21.76% | -28.02% | 12.75% | 24.10% | 28.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.76% | -28.02% | 12.75% | 24.10% | 28.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.76% | -28.02% | 12.75% | 24.10% | 28.81% |
| EBIT | -7.44% | -16.46% | 0.33% | 8.92% | 18.30% |
| EBITDA | -7.42% | -16.55% | 0.35% | 8.99% | 18.41% |
| EPS Basic | 3.68% | -19.85% | 16.87% | 26.04% | 26.49% |
| Normalized Basic EPS | 3.53% | -20.00% | 16.50% | 25.71% | 26.09% |
| EPS Diluted | 3.68% | -19.85% | 16.87% | 26.04% | 26.49% |
| Normalized Diluted EPS | 3.53% | -20.00% | 16.50% | 25.71% | 26.09% |
| Average Basic Shares Outstanding | 244.38% | 6.06% | 3.77% | 1.64% | -2.63% |
| Average Diluted Shares Outstanding | 244.38% | 6.06% | 3.77% | 1.64% | -2.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |